Recent News

• 02.03.2026 - Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026
• 01.13.2026 - Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease
• 01.08.2026 - Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology
• 01.06.2026 - Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program
• 12.18.2025 - Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion
• 12.12.2025 - Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease
• 12.12.2025 - Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease
• 11.26.2025 - Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
• 11.25.2025 - Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update
• 11.19.2025 - Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference

Recent Filings

• 01.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 11.25.2025 - 8-K Current report
• 11.25.2025 - EX-99.1 EX-99.1
• 11.25.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 11.14.2025 - EX-99.1 EX-99.1
• 11.14.2025 - 8-K Current report